- Home
- HXHX vs BCAB Comparison
HXHX vs BCAB Comparison
Compare HXHX & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HXHX | BCAB |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | China | United States |
| Employees | 85 | N/A |
| Industry | Trucking Freight/Courier Services | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 6.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HXHX | BCAB |
|---|---|---|
| Price | $0.51 | $4.07 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.3M | 60.5K |
| Earning Date | 05-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $0.12 |
| 52 Week High | $1.84 | $6.52 |
Technical Indicators
Market Signals| Indicator | HXHX | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 52.93 | 53.42 |
| Support Level | $0.51 | $3.92 |
| Resistance Level | $0.56 | $4.22 |
| Average True Range (ATR) | 0.06 | 0.38 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 73.04 | 49.64 |
Price Performance
Historical ComparisonAbout HXHX Haoxin Holdings Limited Class A Ordinary Shares
Haoxin Holdings Ltd is engaged in the logistics industry, including container provider of temperature-controlled truckload service and urban delivery services in China, freight forwarding, cold chain transportation and other businesses. The types of goods involved are all kinds of new energy materials that require low temperature, heat preservation, and constant temperature, electronic products, medicines, meat, fruits, vegetables and others.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.